Undisclosed next gen prostate cancer therapeutic / Radiopharm Theranostics - LARVOL DELTA

Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals (GlobeNewswire) - "Radiopharm Theranostics...is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer....Radiopharm Theranostics (USA) Inc., has entered a stock purchase agreement (Agreement) to acquire 100% of Pharma15 shares effective 3 March 2023 AEDT."

Licensing / partnership • Oncology • Prostate Cancer